Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Mar 1;142(3):e8.
doi: 10.1093/brain/awz005.

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis

Charalampia Papadopoulou  1 , Ying Hong  1 , Ebun Omoyinmi  1 , Paul A Brogan  1 , Despina Eleftheriou  1   2
Affiliations
Comment

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis

Charalampia Papadopoulou et al. Brain. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical and interferon (IFN) biomarker response in a patient with JDM treated with janus kinase (JAK) 1/2 inhibitor (baricitinib). (A and B) Improvement in facial skin rash in an 11-year-old male patient with JDM treated with baricitinib. (C) IFN induced gene expression at baseline, 6 months, 12 months (flare) and 18 months after starting baricitinib, compared to healthy controls (HC, n = 13). (D) Signal transducer and activator of transcription 1 (STAT1) phosphorylation in CD4+ cells and (E) in CD14+ cells assessed with flow cytometry is shown at time of starting baricitinib treatment baseline (t = 0 months), 6 months, 12 months (flare) and 18 months compared to healthy controls (n = 3). (F) Circulating endothelial cells (CECs) were measured with immunomagnetic bead extraction at baseline before treatment with baricitinib was started and at 6 months, 12 months (flare) and 18 months after starting treatment. Results are expressed as median and range. MFI = median fluorescence intensity.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 2011; 13: 249. - PMC - PubMed
    1. Campanilho-Marques R, Almeida B, Deakin C, Arnold K, Gallot N, de Iorio M, et al.Comparison of the utility and validity of three scoring tools to measure skin involvement in patients with juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2016; 68: 1514–21. - PMC - PubMed
    1. Clarke LA, Hong Y, Eleftheriou D, Shah V, Arrigoni F, Klein NJ, et al.Endothelial injury and repair in systemic vasculitis of the young. Arthritis Rheum 2010; 62: 1770–80. - PubMed
    1. Ladislau L, Suarez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, et al.JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 2018; 141: 1609–21. - PubMed
    1. Omoyinmi E, Standing A, Keylock A, Price-Kuehne F, Melo Gomes S, Rowczenio D, et al.Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis. PLoS One 2017; 12: e0181874. - PMC - PubMed